Basilea BAL8557 Phase II data

Basilea (SWX:BSLN) said BAL8557 met the primary endpoint of non-inferiority to fluconazole on endoscopically confirmed clinical cure in a Phase II trial to treat esophageal candidiasis. In the double-...